@Tony barber, the probable lower price for trof worldwide has already been a known factor for quite some time, and would have been taken into account when the ROW agreement was negotiated on both sides - Acadia would have been aware of it but also had launched DAYBUE three months prior into the US and saw positive data and potential (and can use learnings from the US for the various ROW launches). Neuren on the other side would have rightly expected (and therefore negotiated) higher royalty percentages than the US deal because the ROW deal was negotiated after FDA approval and a positive US launch. Therefore everything should be priced in on this - Acadia and Neuren would have been aware of the economics of the deal (and remember that there was $100m upfront involved from Acadia) and informed investors would be aware that higher royalty percentages would likely be somewhat offset by a lower average ROW price.
NEU Price at posting:
$16.54 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)